JP2024527974A - 小細胞肺がんを治療する薬物の組み合わせ - Google Patents

小細胞肺がんを治療する薬物の組み合わせ Download PDF

Info

Publication number
JP2024527974A
JP2024527974A JP2024504984A JP2024504984A JP2024527974A JP 2024527974 A JP2024527974 A JP 2024527974A JP 2024504984 A JP2024504984 A JP 2024504984A JP 2024504984 A JP2024504984 A JP 2024504984A JP 2024527974 A JP2024527974 A JP 2024527974A
Authority
JP
Japan
Prior art keywords
antibody
seq
anlotinib
drug combination
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527974A5 (cg-RX-API-DMAC7.html
Inventor
ジャン,シーチュエン
ワン,シュンチアン
ユー,ディン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2024527974A publication Critical patent/JP2024527974A/ja
Publication of JP2024527974A5 publication Critical patent/JP2024527974A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024504984A 2021-08-05 2022-08-05 小細胞肺がんを治療する薬物の組み合わせ Pending JP2024527974A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110897167.2 2021-08-05
CN202110897167 2021-08-05
PCT/CN2022/110539 WO2023011631A1 (zh) 2021-08-05 2022-08-05 治疗小细胞肺癌的药物组合

Publications (2)

Publication Number Publication Date
JP2024527974A true JP2024527974A (ja) 2024-07-26
JP2024527974A5 JP2024527974A5 (cg-RX-API-DMAC7.html) 2025-08-13

Family

ID=85154833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504984A Pending JP2024527974A (ja) 2021-08-05 2022-08-05 小細胞肺がんを治療する薬物の組み合わせ

Country Status (8)

Country Link
US (1) US20240343807A1 (cg-RX-API-DMAC7.html)
EP (1) EP4382123A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527974A (cg-RX-API-DMAC7.html)
KR (1) KR20240046526A (cg-RX-API-DMAC7.html)
CN (1) CN116209443A (cg-RX-API-DMAC7.html)
AU (1) AU2022321783A1 (cg-RX-API-DMAC7.html)
CA (1) CA3227992A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023011631A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118267468A (zh) * 2019-01-25 2024-07-02 正大天晴药业集团股份有限公司 治疗肿瘤的联用药物组合物
WO2024155790A2 (en) * 2023-01-18 2024-07-25 Onkosxcel Therapeutics, Llc Novel approach for treatment of cancer using immunomodulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201901057UA (en) * 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
CN116077647B (zh) * 2018-07-18 2025-06-27 正大天晴药业集团股份有限公司 喹啉衍生物与抗体的药物组合
SG11202102682SA (en) * 2018-09-18 2021-04-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Quinoline derivative used for treating small cell lung cancer
CN111617243B (zh) * 2019-02-28 2023-12-19 正大天晴药业集团股份有限公司 喹啉衍生物与抗体的药物组合
BR112021017678A2 (pt) * 2019-03-07 2021-11-16 Advenchen Pharmaceuticals Llc Uso de catequentinibe (anlotinibe) combinando com quimioterapia padrão ou imunoterapia em ordem sequencial para o tratamento de câncer
CN113613674B (zh) * 2019-03-15 2024-11-05 正大天晴药业集团股份有限公司 治疗小细胞肺癌的联用药物组合物
JP7761490B2 (ja) * 2019-05-20 2025-10-30 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 小細胞肺がんの併用療法用キノリン誘導体
WO2020249018A1 (zh) * 2019-06-10 2020-12-17 正大天晴药业集团南京顺欣制药有限公司 治疗驱动基因阳性肺癌的联用药物组合物
WO2022002153A1 (zh) * 2020-06-30 2022-01-06 正大天晴药业集团股份有限公司 用于治疗肿瘤的药物

Also Published As

Publication number Publication date
WO2023011631A1 (zh) 2023-02-09
EP4382123A4 (en) 2025-09-17
AU2022321783A1 (en) 2024-03-14
US20240343807A1 (en) 2024-10-17
CA3227992A1 (en) 2023-02-09
KR20240046526A (ko) 2024-04-09
CN116209443A (zh) 2023-06-02
EP4382123A1 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
CN113613674B (zh) 治疗小细胞肺癌的联用药物组合物
JP7582952B2 (ja) 腫瘍治療用の併用医薬組成物
EP4442710A1 (en) Drug combination for treating non-small cell lung cancer
WO2020249018A1 (zh) 治疗驱动基因阳性肺癌的联用药物组合物
WO2021219138A1 (zh) 用于治疗肾癌的联用药物
CN120437288A (zh) 治疗卵巢癌的药物组合
US20240343807A1 (en) Pharmaceutical composition for treating small cell lung cancer
EP4197554A1 (en) Combined medication for treating soft tissue sarcoma
RU2830590C2 (ru) Комбинированный лекарственный препарат для лечения рака почек
HK40110592A (en) Pharmaceutical composition for treating small cell lung cancer
RU2829637C2 (ru) Комбинированная фармацевтическая композиция для лечения опухоли
HK40118252A (en) Drug combination for treating non-small cell lung cancer
US20240316031A1 (en) Combination drug for treatment of gastric carcinoma and/or esophagogastric junction cancer
CN117642181A (zh) 用于治疗食管癌的药物组合
CN116036265A (zh) 用于癌症的联用药物
HK40113045A (en) Combined pharmaceutical composition for treating tumor
HK40083393A (en) Combination drug for treating kidney cancer
HK40085501A (en) Combination drug for treating kidney cancer
CN114667159A (zh) 喹啉衍生物与pd-1单抗的药物组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250804